DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Risperdal (Risperidone) - Summary

 


Nutrilib.com
A comprihensive source of nutritional information

Increased Mortality in Elderly Patients with Dementia–Related Psychosis

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Analyses of seventeen placebo controlled trials (modal duration of 10 weeks) in these patients revealed a risk of death in the drug-treated patients of between 1.6 to 1.7 times that seen in placebo-treated patients. Over the course of a typical 10 week controlled trial, the rate of death in drug-treated patients was about 4.5%, compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature. RISPERDAL® (risperidone) is not approved for the treatment of patients with Dementia-Related Psychosis.

 

RISPERDAL SUMMARY

RISPERDAL®
(risperidone)
TABLETS/ORAL SOLUTION
RISPERDAL® M-TAB®
(risperidone)
ORALLY DISINTEGRATING TABLETS

RISPERDAL® (risperidone) is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives. The chemical designation is 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl] -6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one.

RISPERDAL® (risperidone) is indicated for the following:

SCHIZOPHRENIA

RISPERDAL® (risperidone) is indicated for the treatment of schizophrenia.

The efficacy of RISPERDAL® in schizophrenia was established in short-term (6- to 8-weeks) controlled trials of schizophrenic inpatients (see CLINICAL PHARMACOLOGY).

The efficacy of RISPERDAL® in delaying relapse was demonstrated in schizophrenic patients who had been clinically stable for at least 4 weeks before initiation of treatment with RISPERDAL® or an active comparator and who were then observed for relapse during a period of 1 to 2 years (see CLINICAL PHARMACOLOGY - Clinical Trials). Nevertheless, the physician who elects to use RISPERDAL® for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION).

BIPOLAR MANIA

Monotherapy

RISPERDAL® is indicated for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder.

The efficacy of RISPERDAL® was established in two placebo-controlled trials (3-week) with patients meeting DSM-IV criteria for Bipolar I Disorder who currently displayed an acute manic or mixed episode with or without psychotic features (see CLINICAL PHARMACOLOGY).

Combination Therapy

The combination of RISPERDAL® with lithium or valproate is indicated for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder.

The efficacy of RISPERDAL® in combination with lithium or valproate was established in one placebo-controlled (3-week) trial with patients meeting DSM-IV criteria for Bipolar I Disorder who currently displayed an acute manic or mixed episode with or without psychotic features (see CLINICAL PHARMACOLOGY).

The effectiveness of RISPERDAL® for longer-term use, that is, for more than 3 weeks of treatment of an acute episode, and for prophylactic use in mania, has not been systematically evaluated in controlled clinical trials. Therefore, physicians who elect to use RISPERDAL® for extended periods should periodically re-evaluate the long-term risks and benefits of the drug for the individual patient (see DOSAGE AND ADMINISTRATION).


See all Risperdal indications & dosage >>

RISPERDAL NEWS HIGHLIGHTS

Media Articles Related to Risperdal (Risperidone)

Teva Announces Appellate Court Reverses Generic Risperdal(R) Exclusivity Decision
Source: Bipolar News From Medical News Today [2008.09.15]

FDA Approves Generic Risperdal
Source: MedicineNet risperidone Specialty [2008.07.02]

more >>

Published Studies Related to Risperdal (Risperidone)

Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. [2008.11]

A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. [2008.08.07]

Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial. [2008.08]

A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. [2008.08]

Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study. [2008.08]

more >>

Clinical Trials Related to Risperdal (Risperidone)

Risperdal Consta for Bipolar Disorder [Active, not recruiting]

Schizophrenia Risperidone vs Olanzapine Study HGMN [Completed]

Evaluation of the Usefulness to Doctors of the Risperdal® Consta® Treatment Guidebook Over a Three-Month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-Acting Risperidone by Injection [Completed]

A Study of How Long it Takes a Patient to Relapse After Switching From an Oral Antipsychotic to One of Two Doses of Long-Acting Risperidone Injections in Patients With Schizophrenia or Schizoaffective Disorder [Completed]

A Prospective Study of Risperdal® (Risperidone) for the Treatment of Behavioral Disorder Following Psychological Therapy for Challenging Behavior in Learning Disabled Children [Completed]

more >>

RISPERDAL PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 1 ratings/reviews, Risperdal has an overall score of 5. The effectiveness score is 4 and the side effect score is 6. The scores are on ten point scale: 10 - best, 1 - worst.
 

Risperdal review by medical professional caring for 50 year old male patient

  Rating
Overall rating:  
Effectiveness:   Marginally Effective
Side effects:   Moderate Side Effects
  
Treatment Info
Condition / reason:   Psychosis
Dosage & duration:   4mg at bed time taken everyday for the period of more than 2 years
Other conditions:   Insomnia and depression
Other drugs taken:   Glyceryl Trinitrate,Clopidogrel,Ecospirin,Sodium Valproate, Glimiperide Metformin and Amlodipine
  
Reported Results
Benefits:   Blood sugar was under control. BP was under control.Sleep was much better.But I had nightmares when I was on a beta-blocker like Metoprolol earlier.Sometimes I had Sinus bradycardia also.In addition, there was an urge to smoke whenever I got up at night.My tongue used to become dry and my speech was slurred.
Side effects:   Restlessness, Constipation,bad dreams etc.
Comments:   Glimeperide-1 mg b.i.d. Metformin 500 mg b.i.d. Amlodipine 5 mg od. Encorate chrono 500 mg b.i.d. Atorvastatin 10 mg o.d. Respidon 3mg b.i.d. Larpose 2mg HS. Becosules-Z o.d.

See all Risperdal reviews / ratings >>

Page last updated: 2008-11-03

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008